Lymphatropic Combination Therapy

Time: 1:30 pm
day: Day Two

Details:

  • Targeting MAPK and PI3K/mTOR pathways is critical due to crosstalk
  • Combination therapy strategies have been hampered by dose-limiting toxicities
  • A Lymphatropic single agent orally bioavailable mutikinase inhibitor provides a path forward

Speakers: